In Response to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis

J.P., R.K., C.M., D.R.S., J.P., J.P., Y.C., D.F.S. declare no conflicts of interest. N.K. reports consultancy with Precigen. Y.P.H reports honoraria from the American Society of Clinical Pathology; royalties from Elsevier, both of which were unrelated to this study. FB reports consultancy with Merck 2023. S.P. reports consultancy with Inovio Pharmaceuticals. N.F.S. reports a compensated or non-compensated advisory role with: Astra Zeneca Eisai Medical Exelixis Merck, EMD Serono, Pfizer, Kura, Vaccinex, CUE, BionTech, GSK, TOSK, Seagen, Flamingo, Infinity, Inovio, Aveo, Medscape, Onclive, Uptodate, BMS, Cornerstone, Celldex, Surface Oncology, Urogen, Astex, Imugene, Faron Pharmaceutical, Coherus, Adagene, Fulgent, Springer, Nanobiotix, Taiho and funding from: Exelixis, BMS. S.R.B. reports consultancy with Inovio and Precigen, S.I.P. has received consultancy payments from AbbVie, AstraZeneca/MedImmune, CUE Biopharma, Fusion Pharmaceuticals, G1 Therapeutics, Incendia, Inovio, MSD, Newlink Genetics, Oncolys Biopharma, Parthenon Therapeutics, Recurrent Respiratory Papillomatosis Foundation, Replimune, Scopus Biopharma, Sensei Biotherapeutics, and Umoja; and research grants from AbbVie, AstraZeneca/MedImmune, CUE Biopharma, Eisai, Merck, Recurrent Respiratory Papillomatosis Foundation, Sensei Biotherapeutics, and Tesaro.